Global Radioimmunoassay Market

Radioimmunoassay Comprehensive Study by Type (Reagents & Kits, Analyzers), Application (Research, Clinical Diagnostics, Others), End-user (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic Labs) Players and Region - Global Market Outlook to 2026

Radioimmunoassay Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Radioimmunoassay Market?

Radioimmunoassay (RIA) is a sensitive and quantitative method used to detect and quantitate the number of antigens in vitro. It is a very important tool in clinical practice and biomedical research. Radioimmunoassay commonly used to assay microbial antigens, vitamins, proteins, hormones, or drugs in serum. The factors such as Increased Prevalence of Cancer and Infectious Diseases and Increased Research and Development Activities are the key factors driving the global Radioimmunoassay market. In addition, Technological Advancement in the Healthcare Sector also fueling market growth. However, the High Cost of Equipment may hamper the market growth.

The market study is being classified by Type (Reagents & Kits and Analyzers), by Application (Research, Clinical Diagnostics and Others) and major geographies with country level break-up.

PerkinElmer, Inc. (United States), DRG International, Inc. (United States), DIAsource ImmunoAssays SA (Belgium), Beckman Coulter, Inc. (United States), IBL International (A Tecan Company) (Germany), MP Biomedicals, LLC (United States), Cisbio (France), Euro Diagnostica AB (Sweden), DiaSorin S.p.A. (Italy), EMD Millipore (United States), Izotop (Hungary), Berthold Technologies GmbH & Co. KG (Germany) and Stratec Biomedical AG (Germany) are some of the key players profiled in the study.

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Radioimmunoassay market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Radioimmunoassay market by Type, Application and Region.

On the basis of geography, the market of Radioimmunoassay has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increased Prevalence of Cancer and Infectious Diseases
  • Increased Research and Development Activities

Market Trend
  • Technological Advancement in the Healthcare Sector

Restraints
  • High Cost of the Equipment

Opportunities
  • Growth in the Healthcare Industry Worldwide
  • Increasing Demand for Healthcare Automation

Challenges
  • Stringent Government Rules and Regulations





Key Target Audience
Radioimmunoassay Equipment Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies, Research Professionals and End-users

Report Objectives / Segmentation Covered

By Type
  • Reagents & Kits
  • Analyzers
By Application
  • Research
  • Clinical Diagnostics
  • Others
By End-user
  • Hospital
  • Pharmaceutical Industry
  • Academics
  • Clinical Diagnostic Labs

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Cancer and Infectious Diseases
      • 3.2.2. Increased Research and Development Activities
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Technological Advancement in the Healthcare Sector
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Radioimmunoassay, by Type, Application, End-user and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Radioimmunoassay (Value)
      • 5.2.1. Global Radioimmunoassay by: Type (Value)
        • 5.2.1.1. Reagents & Kits
        • 5.2.1.2. Analyzers
      • 5.2.2. Global Radioimmunoassay by: Application (Value)
        • 5.2.2.1. Research
        • 5.2.2.2. Clinical Diagnostics
        • 5.2.2.3. Others
      • 5.2.3. Global Radioimmunoassay by: End-user (Value)
        • 5.2.3.1. Hospital
        • 5.2.3.2. Pharmaceutical Industry
        • 5.2.3.3. Academics
        • 5.2.3.4. Clinical Diagnostic Labs
      • 5.2.4. Global Radioimmunoassay Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Radioimmunoassay (Volume)
      • 5.3.1. Global Radioimmunoassay by: Type (Volume)
        • 5.3.1.1. Reagents & Kits
        • 5.3.1.2. Analyzers
      • 5.3.2. Global Radioimmunoassay by: Application (Volume)
        • 5.3.2.1. Research
        • 5.3.2.2. Clinical Diagnostics
        • 5.3.2.3. Others
      • 5.3.3. Global Radioimmunoassay by: End-user (Volume)
        • 5.3.3.1. Hospital
        • 5.3.3.2. Pharmaceutical Industry
        • 5.3.3.3. Academics
        • 5.3.3.4. Clinical Diagnostic Labs
      • 5.3.4. Global Radioimmunoassay Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Radioimmunoassay (Price)
      • 5.4.1. Global Radioimmunoassay by: Type (Price)
  • 6. Radioimmunoassay: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. PerkinElmer, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. DRG International, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. DIAsource ImmunoAssays SA (Belgium)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Beckman Coulter, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. IBL International (A Tecan Company) (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. MP Biomedicals, LLC (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Cisbio (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Euro Diagnostica AB (Sweden)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. DiaSorin S.p.A. (Italy)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. EMD Millipore (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Izotop (Hungary)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Berthold Technologies GmbH & Co. KG (Germany)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Stratec Biomedical AG (Germany)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Radioimmunoassay Sale, by Type, Application, End-user and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Radioimmunoassay (Value)
      • 7.2.1. Global Radioimmunoassay by: Type (Value)
        • 7.2.1.1. Reagents & Kits
        • 7.2.1.2. Analyzers
      • 7.2.2. Global Radioimmunoassay by: Application (Value)
        • 7.2.2.1. Research
        • 7.2.2.2. Clinical Diagnostics
        • 7.2.2.3. Others
      • 7.2.3. Global Radioimmunoassay by: End-user (Value)
        • 7.2.3.1. Hospital
        • 7.2.3.2. Pharmaceutical Industry
        • 7.2.3.3. Academics
        • 7.2.3.4. Clinical Diagnostic Labs
      • 7.2.4. Global Radioimmunoassay Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Radioimmunoassay (Volume)
      • 7.3.1. Global Radioimmunoassay by: Type (Volume)
        • 7.3.1.1. Reagents & Kits
        • 7.3.1.2. Analyzers
      • 7.3.2. Global Radioimmunoassay by: Application (Volume)
        • 7.3.2.1. Research
        • 7.3.2.2. Clinical Diagnostics
        • 7.3.2.3. Others
      • 7.3.3. Global Radioimmunoassay by: End-user (Volume)
        • 7.3.3.1. Hospital
        • 7.3.3.2. Pharmaceutical Industry
        • 7.3.3.3. Academics
        • 7.3.3.4. Clinical Diagnostic Labs
      • 7.3.4. Global Radioimmunoassay Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Radioimmunoassay (Price)
      • 7.4.1. Global Radioimmunoassay by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Radioimmunoassay: by Type(USD Million)
  • Table 2. Radioimmunoassay Reagents & Kits , by Region USD Million (2015-2020)
  • Table 3. Radioimmunoassay Analyzers , by Region USD Million (2015-2020)
  • Table 4. Radioimmunoassay: by Application(USD Million)
  • Table 5. Radioimmunoassay Research , by Region USD Million (2015-2020)
  • Table 6. Radioimmunoassay Clinical Diagnostics , by Region USD Million (2015-2020)
  • Table 7. Radioimmunoassay Others , by Region USD Million (2015-2020)
  • Table 8. Radioimmunoassay: by End-user(USD Million)
  • Table 9. Radioimmunoassay Hospital , by Region USD Million (2015-2020)
  • Table 10. Radioimmunoassay Pharmaceutical Industry , by Region USD Million (2015-2020)
  • Table 11. Radioimmunoassay Academics , by Region USD Million (2015-2020)
  • Table 12. Radioimmunoassay Clinical Diagnostic Labs , by Region USD Million (2015-2020)
  • Table 13. South America Radioimmunoassay, by Country USD Million (2015-2020)
  • Table 14. South America Radioimmunoassay, by Type USD Million (2015-2020)
  • Table 15. South America Radioimmunoassay, by Application USD Million (2015-2020)
  • Table 16. South America Radioimmunoassay, by End-user USD Million (2015-2020)
  • Table 17. Brazil Radioimmunoassay, by Type USD Million (2015-2020)
  • Table 18. Brazil Radioimmunoassay, by Application USD Million (2015-2020)
  • Table 19. Brazil Radioimmunoassay, by End-user USD Million (2015-2020)
  • Table 20. Argentina Radioimmunoassay, by Type USD Million (2015-2020)
  • Table 21. Argentina Radioimmunoassay, by Application USD Million (2015-2020)
  • Table 22. Argentina Radioimmunoassay, by End-user USD Million (2015-2020)
  • Table 23. Rest of South America Radioimmunoassay, by Type USD Million (2015-2020)
  • Table 24. Rest of South America Radioimmunoassay, by Application USD Million (2015-2020)
  • Table 25. Rest of South America Radioimmunoassay, by End-user USD Million (2015-2020)
  • Table 26. Asia Pacific Radioimmunoassay, by Country USD Million (2015-2020)
  • Table 27. Asia Pacific Radioimmunoassay, by Type USD Million (2015-2020)
  • Table 28. Asia Pacific Radioimmunoassay, by Application USD Million (2015-2020)
  • Table 29. Asia Pacific Radioimmunoassay, by End-user USD Million (2015-2020)
  • Table 30. China Radioimmunoassay, by Type USD Million (2015-2020)
  • Table 31. China Radioimmunoassay, by Application USD Million (2015-2020)
  • Table 32. China Radioimmunoassay, by End-user USD Million (2015-2020)
  • Table 33. Japan Radioimmunoassay, by Type USD Million (2015-2020)
  • Table 34. Japan Radioimmunoassay, by Application USD Million (2015-2020)
  • Table 35. Japan Radioimmunoassay, by End-user USD Million (2015-2020)
  • Table 36. India Radioimmunoassay, by Type USD Million (2015-2020)
  • Table 37. India Radioimmunoassay, by Application USD Million (2015-2020)
  • Table 38. India Radioimmunoassay, by End-user USD Million (2015-2020)
  • Table 39. South Korea Radioimmunoassay, by Type USD Million (2015-2020)
  • Table 40. South Korea Radioimmunoassay, by Application USD Million (2015-2020)
  • Table 41. South Korea Radioimmunoassay, by End-user USD Million (2015-2020)
  • Table 42. Taiwan Radioimmunoassay, by Type USD Million (2015-2020)
  • Table 43. Taiwan Radioimmunoassay, by Application USD Million (2015-2020)
  • Table 44. Taiwan Radioimmunoassay, by End-user USD Million (2015-2020)
  • Table 45. Australia Radioimmunoassay, by Type USD Million (2015-2020)
  • Table 46. Australia Radioimmunoassay, by Application USD Million (2015-2020)
  • Table 47. Australia Radioimmunoassay, by End-user USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Radioimmunoassay, by Type USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Radioimmunoassay, by Application USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Radioimmunoassay, by End-user USD Million (2015-2020)
  • Table 51. Europe Radioimmunoassay, by Country USD Million (2015-2020)
  • Table 52. Europe Radioimmunoassay, by Type USD Million (2015-2020)
  • Table 53. Europe Radioimmunoassay, by Application USD Million (2015-2020)
  • Table 54. Europe Radioimmunoassay, by End-user USD Million (2015-2020)
  • Table 55. Germany Radioimmunoassay, by Type USD Million (2015-2020)
  • Table 56. Germany Radioimmunoassay, by Application USD Million (2015-2020)
  • Table 57. Germany Radioimmunoassay, by End-user USD Million (2015-2020)
  • Table 58. France Radioimmunoassay, by Type USD Million (2015-2020)
  • Table 59. France Radioimmunoassay, by Application USD Million (2015-2020)
  • Table 60. France Radioimmunoassay, by End-user USD Million (2015-2020)
  • Table 61. Italy Radioimmunoassay, by Type USD Million (2015-2020)
  • Table 62. Italy Radioimmunoassay, by Application USD Million (2015-2020)
  • Table 63. Italy Radioimmunoassay, by End-user USD Million (2015-2020)
  • Table 64. United Kingdom Radioimmunoassay, by Type USD Million (2015-2020)
  • Table 65. United Kingdom Radioimmunoassay, by Application USD Million (2015-2020)
  • Table 66. United Kingdom Radioimmunoassay, by End-user USD Million (2015-2020)
  • Table 67. Netherlands Radioimmunoassay, by Type USD Million (2015-2020)
  • Table 68. Netherlands Radioimmunoassay, by Application USD Million (2015-2020)
  • Table 69. Netherlands Radioimmunoassay, by End-user USD Million (2015-2020)
  • Table 70. Rest of Europe Radioimmunoassay, by Type USD Million (2015-2020)
  • Table 71. Rest of Europe Radioimmunoassay, by Application USD Million (2015-2020)
  • Table 72. Rest of Europe Radioimmunoassay, by End-user USD Million (2015-2020)
  • Table 73. MEA Radioimmunoassay, by Country USD Million (2015-2020)
  • Table 74. MEA Radioimmunoassay, by Type USD Million (2015-2020)
  • Table 75. MEA Radioimmunoassay, by Application USD Million (2015-2020)
  • Table 76. MEA Radioimmunoassay, by End-user USD Million (2015-2020)
  • Table 77. Middle East Radioimmunoassay, by Type USD Million (2015-2020)
  • Table 78. Middle East Radioimmunoassay, by Application USD Million (2015-2020)
  • Table 79. Middle East Radioimmunoassay, by End-user USD Million (2015-2020)
  • Table 80. Africa Radioimmunoassay, by Type USD Million (2015-2020)
  • Table 81. Africa Radioimmunoassay, by Application USD Million (2015-2020)
  • Table 82. Africa Radioimmunoassay, by End-user USD Million (2015-2020)
  • Table 83. North America Radioimmunoassay, by Country USD Million (2015-2020)
  • Table 84. North America Radioimmunoassay, by Type USD Million (2015-2020)
  • Table 85. North America Radioimmunoassay, by Application USD Million (2015-2020)
  • Table 86. North America Radioimmunoassay, by End-user USD Million (2015-2020)
  • Table 87. United States Radioimmunoassay, by Type USD Million (2015-2020)
  • Table 88. United States Radioimmunoassay, by Application USD Million (2015-2020)
  • Table 89. United States Radioimmunoassay, by End-user USD Million (2015-2020)
  • Table 90. Canada Radioimmunoassay, by Type USD Million (2015-2020)
  • Table 91. Canada Radioimmunoassay, by Application USD Million (2015-2020)
  • Table 92. Canada Radioimmunoassay, by End-user USD Million (2015-2020)
  • Table 93. Mexico Radioimmunoassay, by Type USD Million (2015-2020)
  • Table 94. Mexico Radioimmunoassay, by Application USD Million (2015-2020)
  • Table 95. Mexico Radioimmunoassay, by End-user USD Million (2015-2020)
  • Table 96. Radioimmunoassay Sales: by Type(K Units)
  • Table 97. Radioimmunoassay Sales Reagents & Kits , by Region K Units (2015-2020)
  • Table 98. Radioimmunoassay Sales Analyzers , by Region K Units (2015-2020)
  • Table 99. Radioimmunoassay Sales: by Application(K Units)
  • Table 100. Radioimmunoassay Sales Research , by Region K Units (2015-2020)
  • Table 101. Radioimmunoassay Sales Clinical Diagnostics , by Region K Units (2015-2020)
  • Table 102. Radioimmunoassay Sales Others , by Region K Units (2015-2020)
  • Table 103. Radioimmunoassay Sales: by End-user(K Units)
  • Table 104. Radioimmunoassay Sales Hospital , by Region K Units (2015-2020)
  • Table 105. Radioimmunoassay Sales Pharmaceutical Industry , by Region K Units (2015-2020)
  • Table 106. Radioimmunoassay Sales Academics , by Region K Units (2015-2020)
  • Table 107. Radioimmunoassay Sales Clinical Diagnostic Labs , by Region K Units (2015-2020)
  • Table 108. South America Radioimmunoassay Sales, by Country K Units (2015-2020)
  • Table 109. South America Radioimmunoassay Sales, by Type K Units (2015-2020)
  • Table 110. South America Radioimmunoassay Sales, by Application K Units (2015-2020)
  • Table 111. South America Radioimmunoassay Sales, by End-user K Units (2015-2020)
  • Table 112. Brazil Radioimmunoassay Sales, by Type K Units (2015-2020)
  • Table 113. Brazil Radioimmunoassay Sales, by Application K Units (2015-2020)
  • Table 114. Brazil Radioimmunoassay Sales, by End-user K Units (2015-2020)
  • Table 115. Argentina Radioimmunoassay Sales, by Type K Units (2015-2020)
  • Table 116. Argentina Radioimmunoassay Sales, by Application K Units (2015-2020)
  • Table 117. Argentina Radioimmunoassay Sales, by End-user K Units (2015-2020)
  • Table 118. Rest of South America Radioimmunoassay Sales, by Type K Units (2015-2020)
  • Table 119. Rest of South America Radioimmunoassay Sales, by Application K Units (2015-2020)
  • Table 120. Rest of South America Radioimmunoassay Sales, by End-user K Units (2015-2020)
  • Table 121. Asia Pacific Radioimmunoassay Sales, by Country K Units (2015-2020)
  • Table 122. Asia Pacific Radioimmunoassay Sales, by Type K Units (2015-2020)
  • Table 123. Asia Pacific Radioimmunoassay Sales, by Application K Units (2015-2020)
  • Table 124. Asia Pacific Radioimmunoassay Sales, by End-user K Units (2015-2020)
  • Table 125. China Radioimmunoassay Sales, by Type K Units (2015-2020)
  • Table 126. China Radioimmunoassay Sales, by Application K Units (2015-2020)
  • Table 127. China Radioimmunoassay Sales, by End-user K Units (2015-2020)
  • Table 128. Japan Radioimmunoassay Sales, by Type K Units (2015-2020)
  • Table 129. Japan Radioimmunoassay Sales, by Application K Units (2015-2020)
  • Table 130. Japan Radioimmunoassay Sales, by End-user K Units (2015-2020)
  • Table 131. India Radioimmunoassay Sales, by Type K Units (2015-2020)
  • Table 132. India Radioimmunoassay Sales, by Application K Units (2015-2020)
  • Table 133. India Radioimmunoassay Sales, by End-user K Units (2015-2020)
  • Table 134. South Korea Radioimmunoassay Sales, by Type K Units (2015-2020)
  • Table 135. South Korea Radioimmunoassay Sales, by Application K Units (2015-2020)
  • Table 136. South Korea Radioimmunoassay Sales, by End-user K Units (2015-2020)
  • Table 137. Taiwan Radioimmunoassay Sales, by Type K Units (2015-2020)
  • Table 138. Taiwan Radioimmunoassay Sales, by Application K Units (2015-2020)
  • Table 139. Taiwan Radioimmunoassay Sales, by End-user K Units (2015-2020)
  • Table 140. Australia Radioimmunoassay Sales, by Type K Units (2015-2020)
  • Table 141. Australia Radioimmunoassay Sales, by Application K Units (2015-2020)
  • Table 142. Australia Radioimmunoassay Sales, by End-user K Units (2015-2020)
  • Table 143. Rest of Asia-Pacific Radioimmunoassay Sales, by Type K Units (2015-2020)
  • Table 144. Rest of Asia-Pacific Radioimmunoassay Sales, by Application K Units (2015-2020)
  • Table 145. Rest of Asia-Pacific Radioimmunoassay Sales, by End-user K Units (2015-2020)
  • Table 146. Europe Radioimmunoassay Sales, by Country K Units (2015-2020)
  • Table 147. Europe Radioimmunoassay Sales, by Type K Units (2015-2020)
  • Table 148. Europe Radioimmunoassay Sales, by Application K Units (2015-2020)
  • Table 149. Europe Radioimmunoassay Sales, by End-user K Units (2015-2020)
  • Table 150. Germany Radioimmunoassay Sales, by Type K Units (2015-2020)
  • Table 151. Germany Radioimmunoassay Sales, by Application K Units (2015-2020)
  • Table 152. Germany Radioimmunoassay Sales, by End-user K Units (2015-2020)
  • Table 153. France Radioimmunoassay Sales, by Type K Units (2015-2020)
  • Table 154. France Radioimmunoassay Sales, by Application K Units (2015-2020)
  • Table 155. France Radioimmunoassay Sales, by End-user K Units (2015-2020)
  • Table 156. Italy Radioimmunoassay Sales, by Type K Units (2015-2020)
  • Table 157. Italy Radioimmunoassay Sales, by Application K Units (2015-2020)
  • Table 158. Italy Radioimmunoassay Sales, by End-user K Units (2015-2020)
  • Table 159. United Kingdom Radioimmunoassay Sales, by Type K Units (2015-2020)
  • Table 160. United Kingdom Radioimmunoassay Sales, by Application K Units (2015-2020)
  • Table 161. United Kingdom Radioimmunoassay Sales, by End-user K Units (2015-2020)
  • Table 162. Netherlands Radioimmunoassay Sales, by Type K Units (2015-2020)
  • Table 163. Netherlands Radioimmunoassay Sales, by Application K Units (2015-2020)
  • Table 164. Netherlands Radioimmunoassay Sales, by End-user K Units (2015-2020)
  • Table 165. Rest of Europe Radioimmunoassay Sales, by Type K Units (2015-2020)
  • Table 166. Rest of Europe Radioimmunoassay Sales, by Application K Units (2015-2020)
  • Table 167. Rest of Europe Radioimmunoassay Sales, by End-user K Units (2015-2020)
  • Table 168. MEA Radioimmunoassay Sales, by Country K Units (2015-2020)
  • Table 169. MEA Radioimmunoassay Sales, by Type K Units (2015-2020)
  • Table 170. MEA Radioimmunoassay Sales, by Application K Units (2015-2020)
  • Table 171. MEA Radioimmunoassay Sales, by End-user K Units (2015-2020)
  • Table 172. Middle East Radioimmunoassay Sales, by Type K Units (2015-2020)
  • Table 173. Middle East Radioimmunoassay Sales, by Application K Units (2015-2020)
  • Table 174. Middle East Radioimmunoassay Sales, by End-user K Units (2015-2020)
  • Table 175. Africa Radioimmunoassay Sales, by Type K Units (2015-2020)
  • Table 176. Africa Radioimmunoassay Sales, by Application K Units (2015-2020)
  • Table 177. Africa Radioimmunoassay Sales, by End-user K Units (2015-2020)
  • Table 178. North America Radioimmunoassay Sales, by Country K Units (2015-2020)
  • Table 179. North America Radioimmunoassay Sales, by Type K Units (2015-2020)
  • Table 180. North America Radioimmunoassay Sales, by Application K Units (2015-2020)
  • Table 181. North America Radioimmunoassay Sales, by End-user K Units (2015-2020)
  • Table 182. United States Radioimmunoassay Sales, by Type K Units (2015-2020)
  • Table 183. United States Radioimmunoassay Sales, by Application K Units (2015-2020)
  • Table 184. United States Radioimmunoassay Sales, by End-user K Units (2015-2020)
  • Table 185. Canada Radioimmunoassay Sales, by Type K Units (2015-2020)
  • Table 186. Canada Radioimmunoassay Sales, by Application K Units (2015-2020)
  • Table 187. Canada Radioimmunoassay Sales, by End-user K Units (2015-2020)
  • Table 188. Mexico Radioimmunoassay Sales, by Type K Units (2015-2020)
  • Table 189. Mexico Radioimmunoassay Sales, by Application K Units (2015-2020)
  • Table 190. Mexico Radioimmunoassay Sales, by End-user K Units (2015-2020)
  • Table 191. Radioimmunoassay: by Type(USD/Units)
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Radioimmunoassay: by Type(USD Million)
  • Table 206. Radioimmunoassay Reagents & Kits , by Region USD Million (2021-2026)
  • Table 207. Radioimmunoassay Analyzers , by Region USD Million (2021-2026)
  • Table 208. Radioimmunoassay: by Application(USD Million)
  • Table 209. Radioimmunoassay Research , by Region USD Million (2021-2026)
  • Table 210. Radioimmunoassay Clinical Diagnostics , by Region USD Million (2021-2026)
  • Table 211. Radioimmunoassay Others , by Region USD Million (2021-2026)
  • Table 212. Radioimmunoassay: by End-user(USD Million)
  • Table 213. Radioimmunoassay Hospital , by Region USD Million (2021-2026)
  • Table 214. Radioimmunoassay Pharmaceutical Industry , by Region USD Million (2021-2026)
  • Table 215. Radioimmunoassay Academics , by Region USD Million (2021-2026)
  • Table 216. Radioimmunoassay Clinical Diagnostic Labs , by Region USD Million (2021-2026)
  • Table 217. South America Radioimmunoassay, by Country USD Million (2021-2026)
  • Table 218. South America Radioimmunoassay, by Type USD Million (2021-2026)
  • Table 219. South America Radioimmunoassay, by Application USD Million (2021-2026)
  • Table 220. South America Radioimmunoassay, by End-user USD Million (2021-2026)
  • Table 221. Brazil Radioimmunoassay, by Type USD Million (2021-2026)
  • Table 222. Brazil Radioimmunoassay, by Application USD Million (2021-2026)
  • Table 223. Brazil Radioimmunoassay, by End-user USD Million (2021-2026)
  • Table 224. Argentina Radioimmunoassay, by Type USD Million (2021-2026)
  • Table 225. Argentina Radioimmunoassay, by Application USD Million (2021-2026)
  • Table 226. Argentina Radioimmunoassay, by End-user USD Million (2021-2026)
  • Table 227. Rest of South America Radioimmunoassay, by Type USD Million (2021-2026)
  • Table 228. Rest of South America Radioimmunoassay, by Application USD Million (2021-2026)
  • Table 229. Rest of South America Radioimmunoassay, by End-user USD Million (2021-2026)
  • Table 230. Asia Pacific Radioimmunoassay, by Country USD Million (2021-2026)
  • Table 231. Asia Pacific Radioimmunoassay, by Type USD Million (2021-2026)
  • Table 232. Asia Pacific Radioimmunoassay, by Application USD Million (2021-2026)
  • Table 233. Asia Pacific Radioimmunoassay, by End-user USD Million (2021-2026)
  • Table 234. China Radioimmunoassay, by Type USD Million (2021-2026)
  • Table 235. China Radioimmunoassay, by Application USD Million (2021-2026)
  • Table 236. China Radioimmunoassay, by End-user USD Million (2021-2026)
  • Table 237. Japan Radioimmunoassay, by Type USD Million (2021-2026)
  • Table 238. Japan Radioimmunoassay, by Application USD Million (2021-2026)
  • Table 239. Japan Radioimmunoassay, by End-user USD Million (2021-2026)
  • Table 240. India Radioimmunoassay, by Type USD Million (2021-2026)
  • Table 241. India Radioimmunoassay, by Application USD Million (2021-2026)
  • Table 242. India Radioimmunoassay, by End-user USD Million (2021-2026)
  • Table 243. South Korea Radioimmunoassay, by Type USD Million (2021-2026)
  • Table 244. South Korea Radioimmunoassay, by Application USD Million (2021-2026)
  • Table 245. South Korea Radioimmunoassay, by End-user USD Million (2021-2026)
  • Table 246. Taiwan Radioimmunoassay, by Type USD Million (2021-2026)
  • Table 247. Taiwan Radioimmunoassay, by Application USD Million (2021-2026)
  • Table 248. Taiwan Radioimmunoassay, by End-user USD Million (2021-2026)
  • Table 249. Australia Radioimmunoassay, by Type USD Million (2021-2026)
  • Table 250. Australia Radioimmunoassay, by Application USD Million (2021-2026)
  • Table 251. Australia Radioimmunoassay, by End-user USD Million (2021-2026)
  • Table 252. Rest of Asia-Pacific Radioimmunoassay, by Type USD Million (2021-2026)
  • Table 253. Rest of Asia-Pacific Radioimmunoassay, by Application USD Million (2021-2026)
  • Table 254. Rest of Asia-Pacific Radioimmunoassay, by End-user USD Million (2021-2026)
  • Table 255. Europe Radioimmunoassay, by Country USD Million (2021-2026)
  • Table 256. Europe Radioimmunoassay, by Type USD Million (2021-2026)
  • Table 257. Europe Radioimmunoassay, by Application USD Million (2021-2026)
  • Table 258. Europe Radioimmunoassay, by End-user USD Million (2021-2026)
  • Table 259. Germany Radioimmunoassay, by Type USD Million (2021-2026)
  • Table 260. Germany Radioimmunoassay, by Application USD Million (2021-2026)
  • Table 261. Germany Radioimmunoassay, by End-user USD Million (2021-2026)
  • Table 262. France Radioimmunoassay, by Type USD Million (2021-2026)
  • Table 263. France Radioimmunoassay, by Application USD Million (2021-2026)
  • Table 264. France Radioimmunoassay, by End-user USD Million (2021-2026)
  • Table 265. Italy Radioimmunoassay, by Type USD Million (2021-2026)
  • Table 266. Italy Radioimmunoassay, by Application USD Million (2021-2026)
  • Table 267. Italy Radioimmunoassay, by End-user USD Million (2021-2026)
  • Table 268. United Kingdom Radioimmunoassay, by Type USD Million (2021-2026)
  • Table 269. United Kingdom Radioimmunoassay, by Application USD Million (2021-2026)
  • Table 270. United Kingdom Radioimmunoassay, by End-user USD Million (2021-2026)
  • Table 271. Netherlands Radioimmunoassay, by Type USD Million (2021-2026)
  • Table 272. Netherlands Radioimmunoassay, by Application USD Million (2021-2026)
  • Table 273. Netherlands Radioimmunoassay, by End-user USD Million (2021-2026)
  • Table 274. Rest of Europe Radioimmunoassay, by Type USD Million (2021-2026)
  • Table 275. Rest of Europe Radioimmunoassay, by Application USD Million (2021-2026)
  • Table 276. Rest of Europe Radioimmunoassay, by End-user USD Million (2021-2026)
  • Table 277. MEA Radioimmunoassay, by Country USD Million (2021-2026)
  • Table 278. MEA Radioimmunoassay, by Type USD Million (2021-2026)
  • Table 279. MEA Radioimmunoassay, by Application USD Million (2021-2026)
  • Table 280. MEA Radioimmunoassay, by End-user USD Million (2021-2026)
  • Table 281. Middle East Radioimmunoassay, by Type USD Million (2021-2026)
  • Table 282. Middle East Radioimmunoassay, by Application USD Million (2021-2026)
  • Table 283. Middle East Radioimmunoassay, by End-user USD Million (2021-2026)
  • Table 284. Africa Radioimmunoassay, by Type USD Million (2021-2026)
  • Table 285. Africa Radioimmunoassay, by Application USD Million (2021-2026)
  • Table 286. Africa Radioimmunoassay, by End-user USD Million (2021-2026)
  • Table 287. North America Radioimmunoassay, by Country USD Million (2021-2026)
  • Table 288. North America Radioimmunoassay, by Type USD Million (2021-2026)
  • Table 289. North America Radioimmunoassay, by Application USD Million (2021-2026)
  • Table 290. North America Radioimmunoassay, by End-user USD Million (2021-2026)
  • Table 291. United States Radioimmunoassay, by Type USD Million (2021-2026)
  • Table 292. United States Radioimmunoassay, by Application USD Million (2021-2026)
  • Table 293. United States Radioimmunoassay, by End-user USD Million (2021-2026)
  • Table 294. Canada Radioimmunoassay, by Type USD Million (2021-2026)
  • Table 295. Canada Radioimmunoassay, by Application USD Million (2021-2026)
  • Table 296. Canada Radioimmunoassay, by End-user USD Million (2021-2026)
  • Table 297. Mexico Radioimmunoassay, by Type USD Million (2021-2026)
  • Table 298. Mexico Radioimmunoassay, by Application USD Million (2021-2026)
  • Table 299. Mexico Radioimmunoassay, by End-user USD Million (2021-2026)
  • Table 300. Radioimmunoassay Sales: by Type(K Units)
  • Table 301. Radioimmunoassay Sales Reagents & Kits , by Region K Units (2021-2026)
  • Table 302. Radioimmunoassay Sales Analyzers , by Region K Units (2021-2026)
  • Table 303. Radioimmunoassay Sales: by Application(K Units)
  • Table 304. Radioimmunoassay Sales Research , by Region K Units (2021-2026)
  • Table 305. Radioimmunoassay Sales Clinical Diagnostics , by Region K Units (2021-2026)
  • Table 306. Radioimmunoassay Sales Others , by Region K Units (2021-2026)
  • Table 307. Radioimmunoassay Sales: by End-user(K Units)
  • Table 308. Radioimmunoassay Sales Hospital , by Region K Units (2021-2026)
  • Table 309. Radioimmunoassay Sales Pharmaceutical Industry , by Region K Units (2021-2026)
  • Table 310. Radioimmunoassay Sales Academics , by Region K Units (2021-2026)
  • Table 311. Radioimmunoassay Sales Clinical Diagnostic Labs , by Region K Units (2021-2026)
  • Table 312. South America Radioimmunoassay Sales, by Country K Units (2021-2026)
  • Table 313. South America Radioimmunoassay Sales, by Type K Units (2021-2026)
  • Table 314. South America Radioimmunoassay Sales, by Application K Units (2021-2026)
  • Table 315. South America Radioimmunoassay Sales, by End-user K Units (2021-2026)
  • Table 316. Brazil Radioimmunoassay Sales, by Type K Units (2021-2026)
  • Table 317. Brazil Radioimmunoassay Sales, by Application K Units (2021-2026)
  • Table 318. Brazil Radioimmunoassay Sales, by End-user K Units (2021-2026)
  • Table 319. Argentina Radioimmunoassay Sales, by Type K Units (2021-2026)
  • Table 320. Argentina Radioimmunoassay Sales, by Application K Units (2021-2026)
  • Table 321. Argentina Radioimmunoassay Sales, by End-user K Units (2021-2026)
  • Table 322. Rest of South America Radioimmunoassay Sales, by Type K Units (2021-2026)
  • Table 323. Rest of South America Radioimmunoassay Sales, by Application K Units (2021-2026)
  • Table 324. Rest of South America Radioimmunoassay Sales, by End-user K Units (2021-2026)
  • Table 325. Asia Pacific Radioimmunoassay Sales, by Country K Units (2021-2026)
  • Table 326. Asia Pacific Radioimmunoassay Sales, by Type K Units (2021-2026)
  • Table 327. Asia Pacific Radioimmunoassay Sales, by Application K Units (2021-2026)
  • Table 328. Asia Pacific Radioimmunoassay Sales, by End-user K Units (2021-2026)
  • Table 329. China Radioimmunoassay Sales, by Type K Units (2021-2026)
  • Table 330. China Radioimmunoassay Sales, by Application K Units (2021-2026)
  • Table 331. China Radioimmunoassay Sales, by End-user K Units (2021-2026)
  • Table 332. Japan Radioimmunoassay Sales, by Type K Units (2021-2026)
  • Table 333. Japan Radioimmunoassay Sales, by Application K Units (2021-2026)
  • Table 334. Japan Radioimmunoassay Sales, by End-user K Units (2021-2026)
  • Table 335. India Radioimmunoassay Sales, by Type K Units (2021-2026)
  • Table 336. India Radioimmunoassay Sales, by Application K Units (2021-2026)
  • Table 337. India Radioimmunoassay Sales, by End-user K Units (2021-2026)
  • Table 338. South Korea Radioimmunoassay Sales, by Type K Units (2021-2026)
  • Table 339. South Korea Radioimmunoassay Sales, by Application K Units (2021-2026)
  • Table 340. South Korea Radioimmunoassay Sales, by End-user K Units (2021-2026)
  • Table 341. Taiwan Radioimmunoassay Sales, by Type K Units (2021-2026)
  • Table 342. Taiwan Radioimmunoassay Sales, by Application K Units (2021-2026)
  • Table 343. Taiwan Radioimmunoassay Sales, by End-user K Units (2021-2026)
  • Table 344. Australia Radioimmunoassay Sales, by Type K Units (2021-2026)
  • Table 345. Australia Radioimmunoassay Sales, by Application K Units (2021-2026)
  • Table 346. Australia Radioimmunoassay Sales, by End-user K Units (2021-2026)
  • Table 347. Rest of Asia-Pacific Radioimmunoassay Sales, by Type K Units (2021-2026)
  • Table 348. Rest of Asia-Pacific Radioimmunoassay Sales, by Application K Units (2021-2026)
  • Table 349. Rest of Asia-Pacific Radioimmunoassay Sales, by End-user K Units (2021-2026)
  • Table 350. Europe Radioimmunoassay Sales, by Country K Units (2021-2026)
  • Table 351. Europe Radioimmunoassay Sales, by Type K Units (2021-2026)
  • Table 352. Europe Radioimmunoassay Sales, by Application K Units (2021-2026)
  • Table 353. Europe Radioimmunoassay Sales, by End-user K Units (2021-2026)
  • Table 354. Germany Radioimmunoassay Sales, by Type K Units (2021-2026)
  • Table 355. Germany Radioimmunoassay Sales, by Application K Units (2021-2026)
  • Table 356. Germany Radioimmunoassay Sales, by End-user K Units (2021-2026)
  • Table 357. France Radioimmunoassay Sales, by Type K Units (2021-2026)
  • Table 358. France Radioimmunoassay Sales, by Application K Units (2021-2026)
  • Table 359. France Radioimmunoassay Sales, by End-user K Units (2021-2026)
  • Table 360. Italy Radioimmunoassay Sales, by Type K Units (2021-2026)
  • Table 361. Italy Radioimmunoassay Sales, by Application K Units (2021-2026)
  • Table 362. Italy Radioimmunoassay Sales, by End-user K Units (2021-2026)
  • Table 363. United Kingdom Radioimmunoassay Sales, by Type K Units (2021-2026)
  • Table 364. United Kingdom Radioimmunoassay Sales, by Application K Units (2021-2026)
  • Table 365. United Kingdom Radioimmunoassay Sales, by End-user K Units (2021-2026)
  • Table 366. Netherlands Radioimmunoassay Sales, by Type K Units (2021-2026)
  • Table 367. Netherlands Radioimmunoassay Sales, by Application K Units (2021-2026)
  • Table 368. Netherlands Radioimmunoassay Sales, by End-user K Units (2021-2026)
  • Table 369. Rest of Europe Radioimmunoassay Sales, by Type K Units (2021-2026)
  • Table 370. Rest of Europe Radioimmunoassay Sales, by Application K Units (2021-2026)
  • Table 371. Rest of Europe Radioimmunoassay Sales, by End-user K Units (2021-2026)
  • Table 372. MEA Radioimmunoassay Sales, by Country K Units (2021-2026)
  • Table 373. MEA Radioimmunoassay Sales, by Type K Units (2021-2026)
  • Table 374. MEA Radioimmunoassay Sales, by Application K Units (2021-2026)
  • Table 375. MEA Radioimmunoassay Sales, by End-user K Units (2021-2026)
  • Table 376. Middle East Radioimmunoassay Sales, by Type K Units (2021-2026)
  • Table 377. Middle East Radioimmunoassay Sales, by Application K Units (2021-2026)
  • Table 378. Middle East Radioimmunoassay Sales, by End-user K Units (2021-2026)
  • Table 379. Africa Radioimmunoassay Sales, by Type K Units (2021-2026)
  • Table 380. Africa Radioimmunoassay Sales, by Application K Units (2021-2026)
  • Table 381. Africa Radioimmunoassay Sales, by End-user K Units (2021-2026)
  • Table 382. North America Radioimmunoassay Sales, by Country K Units (2021-2026)
  • Table 383. North America Radioimmunoassay Sales, by Type K Units (2021-2026)
  • Table 384. North America Radioimmunoassay Sales, by Application K Units (2021-2026)
  • Table 385. North America Radioimmunoassay Sales, by End-user K Units (2021-2026)
  • Table 386. United States Radioimmunoassay Sales, by Type K Units (2021-2026)
  • Table 387. United States Radioimmunoassay Sales, by Application K Units (2021-2026)
  • Table 388. United States Radioimmunoassay Sales, by End-user K Units (2021-2026)
  • Table 389. Canada Radioimmunoassay Sales, by Type K Units (2021-2026)
  • Table 390. Canada Radioimmunoassay Sales, by Application K Units (2021-2026)
  • Table 391. Canada Radioimmunoassay Sales, by End-user K Units (2021-2026)
  • Table 392. Mexico Radioimmunoassay Sales, by Type K Units (2021-2026)
  • Table 393. Mexico Radioimmunoassay Sales, by Application K Units (2021-2026)
  • Table 394. Mexico Radioimmunoassay Sales, by End-user K Units (2021-2026)
  • Table 395. Radioimmunoassay: by Type(USD/Units)
  • Table 396. Research Programs/Design for This Report
  • Table 397. Key Data Information from Secondary Sources
  • Table 398. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Radioimmunoassay: by Type USD Million (2015-2020)
  • Figure 5. Global Radioimmunoassay: by Application USD Million (2015-2020)
  • Figure 6. Global Radioimmunoassay: by End-user USD Million (2015-2020)
  • Figure 7. South America Radioimmunoassay Share (%), by Country
  • Figure 8. Asia Pacific Radioimmunoassay Share (%), by Country
  • Figure 9. Europe Radioimmunoassay Share (%), by Country
  • Figure 10. MEA Radioimmunoassay Share (%), by Country
  • Figure 11. North America Radioimmunoassay Share (%), by Country
  • Figure 12. Global Radioimmunoassay: by Type K Units (2015-2020)
  • Figure 13. Global Radioimmunoassay: by Application K Units (2015-2020)
  • Figure 14. Global Radioimmunoassay: by End-user K Units (2015-2020)
  • Figure 15. South America Radioimmunoassay Share (%), by Country
  • Figure 16. Asia Pacific Radioimmunoassay Share (%), by Country
  • Figure 17. Europe Radioimmunoassay Share (%), by Country
  • Figure 18. MEA Radioimmunoassay Share (%), by Country
  • Figure 19. North America Radioimmunoassay Share (%), by Country
  • Figure 20. Global Radioimmunoassay: by Type USD/Units (2015-2020)
  • Figure 21. Global Radioimmunoassay share by Players 2020 (%)
  • Figure 22. Global Radioimmunoassay share by Players (Top 3) 2020(%)
  • Figure 23. Global Radioimmunoassay share by Players (Top 5) 2020(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. PerkinElmer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. PerkinElmer, Inc. (United States) Revenue: by Geography 2020
  • Figure 27. DRG International, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. DRG International, Inc. (United States) Revenue: by Geography 2020
  • Figure 29. DIAsource ImmunoAssays SA (Belgium) Revenue, Net Income and Gross profit
  • Figure 30. DIAsource ImmunoAssays SA (Belgium) Revenue: by Geography 2020
  • Figure 31. Beckman Coulter, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Beckman Coulter, Inc. (United States) Revenue: by Geography 2020
  • Figure 33. IBL International (A Tecan Company) (Germany) Revenue, Net Income and Gross profit
  • Figure 34. IBL International (A Tecan Company) (Germany) Revenue: by Geography 2020
  • Figure 35. MP Biomedicals, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 36. MP Biomedicals, LLC (United States) Revenue: by Geography 2020
  • Figure 37. Cisbio (France) Revenue, Net Income and Gross profit
  • Figure 38. Cisbio (France) Revenue: by Geography 2020
  • Figure 39. Euro Diagnostica AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 40. Euro Diagnostica AB (Sweden) Revenue: by Geography 2020
  • Figure 41. DiaSorin S.p.A. (Italy) Revenue, Net Income and Gross profit
  • Figure 42. DiaSorin S.p.A. (Italy) Revenue: by Geography 2020
  • Figure 43. EMD Millipore (United States) Revenue, Net Income and Gross profit
  • Figure 44. EMD Millipore (United States) Revenue: by Geography 2020
  • Figure 45. Izotop (Hungary) Revenue, Net Income and Gross profit
  • Figure 46. Izotop (Hungary) Revenue: by Geography 2020
  • Figure 47. Berthold Technologies GmbH & Co. KG (Germany) Revenue, Net Income and Gross profit
  • Figure 48. Berthold Technologies GmbH & Co. KG (Germany) Revenue: by Geography 2020
  • Figure 49. Stratec Biomedical AG (Germany) Revenue, Net Income and Gross profit
  • Figure 50. Stratec Biomedical AG (Germany) Revenue: by Geography 2020
  • Figure 51. Global Radioimmunoassay: by Type USD Million (2021-2026)
  • Figure 52. Global Radioimmunoassay: by Application USD Million (2021-2026)
  • Figure 53. Global Radioimmunoassay: by End-user USD Million (2021-2026)
  • Figure 54. South America Radioimmunoassay Share (%), by Country
  • Figure 55. Asia Pacific Radioimmunoassay Share (%), by Country
  • Figure 56. Europe Radioimmunoassay Share (%), by Country
  • Figure 57. MEA Radioimmunoassay Share (%), by Country
  • Figure 58. North America Radioimmunoassay Share (%), by Country
  • Figure 59. Global Radioimmunoassay: by Type K Units (2021-2026)
  • Figure 60. Global Radioimmunoassay: by Application K Units (2021-2026)
  • Figure 61. Global Radioimmunoassay: by End-user K Units (2021-2026)
  • Figure 62. South America Radioimmunoassay Share (%), by Country
  • Figure 63. Asia Pacific Radioimmunoassay Share (%), by Country
  • Figure 64. Europe Radioimmunoassay Share (%), by Country
  • Figure 65. MEA Radioimmunoassay Share (%), by Country
  • Figure 66. North America Radioimmunoassay Share (%), by Country
  • Figure 67. Global Radioimmunoassay: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • PerkinElmer, Inc. (United States)
  • DRG International, Inc. (United States)
  • DIAsource ImmunoAssays SA (Belgium)
  • Beckman Coulter, Inc. (United States)
  • IBL International (A Tecan Company) (Germany)
  • MP Biomedicals, LLC (United States)
  • Cisbio (France)
  • Euro Diagnostica AB (Sweden)
  • DiaSorin S.p.A. (Italy)
  • EMD Millipore (United States)
  • Izotop (Hungary)
  • Berthold Technologies GmbH & Co. KG (Germany)
  • Stratec Biomedical AG (Germany)
Select User Access Type

Key Highlights of Report


Mar 2021 222 Pages 84 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Radioimmunoassay Market Quantitative research analysis
Global Radioimmunoassay Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increased Prevalence of Cancer and Infectious Diseases " is seen as one of major growth factors of Radioimmunoassay Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global Radioimmunoassay Market Report?

Have a Query? Click Here

Other Related Reports

Bowel Management Systems Comprehensive Study by Type (Irrigation Systems, Nerve Modulation Devices, Colostomy Bags, Others), Application (Hospitals and Ambulatory Surgery Centers, Home Care, Others),...
$ 3350
Cardiac Valve Repair Comprehensive Study by Type (Trans-Catheter Heart Valve, Tissue Heart Valve, Mechanical Heart Valve, Others), Disease (Aortic Valve Replacement, Mitral Valve Stenosis, Heart Va...
$ 3450
eClinical Solutions Comprehensive Study by Type (Web-hosted (On-demand), Licensed Enterprise (On-premise), Cloud-based (SaaS)), Application (Pharmaceutical and Biopharmaceutical Companies, Contract R...
$ 3450
Healthcare Mobility Solutions Comprehensive Study by Type (Mobile Devices, Mobile Apps, Enterprise Platforms), Application (Enterprise Solutions (Patient Care Management, Operations Management, Workf...
$ 3750
Cardiac Pacing Comprehensive Study by Type (Temporary, Single-Chamber, Dual-Chamber, Single-Chamber ICD, Dual-Chamber ICD), Application (Bradycardia, Atrial fibrillation, Heart failure, Syncope), End...
$ 3450
Stroke Management Comprehensive Study by Type (Ischemic, Hemorrhagic, Transient Ischemic Attack (TIA))), Application (Hospitals, Ambulatory Surgery Centers, Diagnostic Centers), Diagnostics (Magnetic...
$ 3750